The new investment will support further development of Pervasis’s innovative Vascugel blood vessel repair therapeutic, presently in two Phase II clinical trials, as well as continuing research into expanding the product’s projected uses into additional vascular and non-vascular applications.
Stephen Bollinger, president of Pervasis Therapeutics, said: “The additional financing will help Pervasis organically grow our pipeline of Vascugel-related therapies to address under-served medical needs in vascular and non-vascular healing, and bring new products for new disease states online, particularly in cardiovascular applications.”